The eight spinouts featured in this showcase are at the forefront of research innovation at King’s, translating research into real-world solutions. Their progress over the last 12 months reflects a commitment to advancing change and impact for people and society. The King’s Spinout Accelerator is part of a broader pipeline, supporting King’s research community to explore impact through the commercial potential of their research. Congratulations and best wishes to all eight future spinouts.
Professor Sir Bashir M. Al-Hashimi (Vice President of Research & Innovation)
10 July 2025
King's celebrates advances in innovation at the Spinout Accelerator Showcase
The King’s community gathered at Bush House to celebrate the conclusion of the inaugural cohort of the King’s Spinout Accelerator and their progress over the last year.
The event, opened by Professor Sir Bashir M. Al-Hashimi (Vice President of Research & Innovation) showcased how academics and researchers from across King’s College London are advancing real change and tangible impact in health, mental healthcare and technology.
Eight spinouts from the Faculty of Life Science & Medicine, Faculty of Natural, Mathematical & Engineering Sciences and the Institute of Psychiatry, Psychology & Neuroscience presented their innovations, followed by questions from a guest panel featuring:
-
Malcolm Ace (Vice President, Finance and Chief Financial Officer)
-
Elif Sancak (Start-up and Spinout Fundraiser)
-
Michael Kyriakides (Principal of Syncona Investment Management Limited)
The King’s Spinout Accelerator is a 12-month programme, transforming early-stage prospective spinouts into robust commercial propositions. Run by the Entrepreneurship Institute, participants access interactive masterclasses led by experts, skill development sessions to explore commercial pathways for impact, implement evidence-based validation and explore partnership opportunities, coaching, a peer-network, desk space and King’s Investor Network.
The Accelerator launched last year, in partnership with King’s Innovation Catalyst, drawing together expertise from Translational Research Support, IP & Licensing and Industry Partnerships, to facilitate the creation of knowledge exchange, ventures and intellectual property.
Over the last 12 months:
-
6/10 ventures have secured investment or grants during acceleration
-
7/10 ventures are likely to spinout and raise investment within 18 months
-
9/10 ventures have progressed to define their business model and plan
-
10/10 grew their team along with their entrepreneurial competencies
One of the ventures PharosAI received £18.9 million in funding from the UK Government to democratise cancer AI research and accelerate the path to cancer care.
King’s support over the past 12 months has been absolutely pivotal. The Spinout Accelerator helped us shift from thinking like academics to thinking like entrepreneurs—engaging with industry, validating our market, and building a real commercial strategy. We simply wouldn’t be where we are now without that structure, coaching and belief in our vision.
Dr Matthew Howard, The Weird Gripper Company
The eight spinouts showcasing their innovations were:
Spinout |
Description |
Academic Lead |
|
Nuclide Therapeutics |
Using precision radionuclide therapies to identify and treat cancers that are resistant to current therapies, eliminating therapy-resistant cancers that currently lack effective treatment options. |
Dr Muhammet Tanc, Faculty of Life Sciences & Medicine |
| mySkin |
A patient-empowering online tool to capture self-reported outcomes and multiple self-taken images over time, to better enable self-diagnosis, monitoring and management of skin diseases. |
Dr Satveer Mahil and Professor Catherine Smith, Faculty of Life Sciences & Medicine |
|
CoGonBar |
A genomic drug for the treatment of acute and chronic nerve injury. |
Professor Jonathan Corcoran, Institute of Psychiatry, Psychology & Neuroscience |
|
The Weird Gripper Company |
A new gripping technology that picks and handles highly deformable, hard-to-model objects and materials, such as wires, cotton threads, hair, fresh herbs, noodles and netting, probably applied in manufacturing. |
Dr Matthew Howard, Faculty of Natural, Mathematical & Engineering Sciences |
|
Proteix |
Proteix is developing and applying plug-in platform technologies, comparable to Lego Game pieces, to create a range of innovative therapeutics. |
Dr Kourosh Ebrahimi, Faculty of Life Sciences & Medicine |
|
PoMEGRANATE |
A platform empowering women and couples to make healthy choices, leading to optimised pregnancy preparation, successful pregnancies and healthy babies. |
Dr Sara White and Dr Angela Flynn, Faculty of Life Sciences & Medicine |
|
Prosemble |
Transforming cancer care with cutting-edge nanoparticle and AI technologies enhancing treatment efficacy while minimising side effects. |
Dr Julien Bergeron, Faculty of Life Sciences & Medicine |
|
PharosAI |
A platform to navigate the path to AI-powered cancer care. |
Professor Anita Grigoriadis and Dr Gregory Verghese, Faculty of Life Sciences & Medicine |
The pitches reflected not just strong science, but a real awareness of the problems these innovations are solving. From AI in cancer care to novel therapeutics and digital health tools, it was clear these ventures have the potential for meaningful real-world impact. What makes King’s special is its ability to bring together deep research, cross-disciplinary thinking, and a growing entrepreneurial mindset — a powerful combination for building scalable, impactful solutions. This is exactly what deep tech investors are excited about right now and it’s what gives these spinouts such strong potential.
Elif Sancak (Start-up and Spinout Fundraiser)
King’s recently announced eight new potential spinouts from five faculties, who will participate in Cohort II of the King’s Spinout Accelerator, including the first from the Dickson Poon School of Law. 38% are women-led. This year’s cohort are advancing innovations in health, tech and security.
Photo credit: David Tett Photography.
In this story
Vice President (Research & Innovation)
Research Fellow
Professor of Dermatology & Therapeutics
Professor of Neuroscience
Reader
Lecturer in Immunology and Drug Discovery
Clinical Senior Lecturer
Professor of Molecular and Digital Pathology